vs
Ginkgo Bioworks Holdings, Inc.（DNA）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
STEM, INC.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.4倍（$47.1M vs $33.4M），STEM, INC.同比增速更快（-15.6% vs -23.8%），过去两年STEM, INC.的营收复合增速更高（36.1% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
DNA vs STEM — 直观对比
营收规模更大
STEM
是对方的1.4倍
$33.4M
营收增速更快
STEM
高出8.3%
-23.8%
两年增速更快
STEM
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $47.1M |
| 净利润 | — | $-16.0M |
| 毛利率 | — | 48.9% |
| 营业利润率 | -211.9% | -17.7% |
| 净利率 | — | -33.9% |
| 营收同比 | -23.8% | -15.6% |
| 净利润同比 | — | 68.8% |
| 每股收益（稀释后） | $-1.41 | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNASTEM
| Q4 25 | $33.4M | $47.1M | ||
| Q3 25 | $38.8M | $38.2M | ||
| Q2 25 | $49.6M | $38.4M | ||
| Q1 25 | $48.3M | $32.5M | ||
| Q4 24 | $43.8M | $55.8M | ||
| Q3 24 | $89.0M | $29.3M | ||
| Q2 24 | $56.2M | $34.0M | ||
| Q1 24 | $37.9M | $25.5M |
净利润DNASTEM
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $-80.8M | $-23.8M | ||
| Q2 25 | $-60.3M | $202.5M | ||
| Q1 25 | $-91.0M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $-56.4M | $-148.3M | ||
| Q2 24 | $-217.2M | $-582.3M | ||
| Q1 24 | $-165.9M | $-72.3M |
毛利率DNASTEM
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
营业利润率DNASTEM
| Q4 25 | -211.9% | -17.7% | ||
| Q3 25 | -231.8% | -33.6% | ||
| Q2 25 | -132.1% | -34.8% | ||
| Q1 25 | -184.1% | -65.0% | ||
| Q4 24 | -236.3% | -84.4% | ||
| Q3 24 | -62.0% | -493.2% | ||
| Q2 24 | -396.7% | -1705.5% | ||
| Q1 24 | -469.1% | -267.0% |
净利率DNASTEM
| Q4 25 | — | -33.9% | ||
| Q3 25 | -207.9% | -62.2% | ||
| Q2 25 | -121.6% | 527.8% | ||
| Q1 25 | -188.2% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | -63.3% | -506.3% | ||
| Q2 24 | -386.4% | -1712.6% | ||
| Q1 24 | -437.3% | -283.9% |
每股收益（稀释后）DNASTEM
| Q4 25 | $-1.41 | $-4.40 | ||
| Q3 25 | $-1.45 | $-2.84 | ||
| Q2 25 | $-1.10 | $-1.79 | ||
| Q1 25 | $-1.68 | $-0.15 | ||
| Q4 24 | $-1.91 | $-15.29 | ||
| Q3 24 | $-1.08 | $-18.24 | ||
| Q2 24 | $-4.23 | $-71.81 | ||
| Q1 24 | $-3.32 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $48.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $-249.4M |
| 总资产 | $1.1B | $308.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNASTEM
| Q4 25 | $422.6M | $48.9M | ||
| Q3 25 | $495.5M | $43.1M | ||
| Q2 25 | $559.4M | $40.8M | ||
| Q1 25 | $325.3M | $58.6M | ||
| Q4 24 | $561.6M | $56.3M | ||
| Q3 24 | $616.2M | $75.4M | ||
| Q2 24 | $730.4M | $89.6M | ||
| Q1 24 | $840.4M | $112.8M |
股东权益DNASTEM
| Q4 25 | $508.6M | $-249.4M | ||
| Q3 25 | $559.8M | $-235.7M | ||
| Q2 25 | $613.0M | $-214.1M | ||
| Q1 25 | $647.4M | $-417.5M | ||
| Q4 24 | $716.1M | $-398.4M | ||
| Q3 24 | $797.9M | $-344.1M | ||
| Q2 24 | $833.1M | $-203.2M | ||
| Q1 24 | $987.3M | $371.6M |
总资产DNASTEM
| Q4 25 | $1.1B | $308.9M | ||
| Q3 25 | $1.2B | $362.6M | ||
| Q2 25 | $1.2B | $379.2M | ||
| Q1 25 | $1.3B | $405.1M | ||
| Q4 24 | $1.4B | $437.4M | ||
| Q3 24 | $1.5B | $537.8M | ||
| Q2 24 | $1.6B | $691.5M | ||
| Q1 24 | $1.6B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | — |
| 自由现金流率自由现金流/营收 | -142.8% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DNASTEM
| Q4 25 | $-47.7M | $8.2M | ||
| Q3 25 | $-31.6M | $11.4M | ||
| Q2 25 | $-40.3M | $-21.3M | ||
| Q1 25 | $-51.5M | $8.5M | ||
| Q4 24 | $-42.4M | $-14.7M | ||
| Q3 24 | $-103.5M | $-9.4M | ||
| Q2 24 | $-84.4M | $-11.9M | ||
| Q1 24 | $-89.3M | $-621.0K |
自由现金流DNASTEM
| Q4 25 | $-47.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-59.1M | — | ||
| Q4 24 | $-56.1M | — | ||
| Q3 24 | $-118.6M | — | ||
| Q2 24 | $-111.4M | — | ||
| Q1 24 | $-96.0M | — |
自由现金流率DNASTEM
| Q4 25 | -142.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -81.2% | — | ||
| Q1 25 | -122.4% | — | ||
| Q4 24 | -128.0% | — | ||
| Q3 24 | -133.2% | — | ||
| Q2 24 | -198.2% | — | ||
| Q1 24 | -252.9% | — |
资本支出强度DNASTEM
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | 31.3% | — | ||
| Q3 24 | 16.9% | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | 17.7% | — |
现金转化率DNASTEM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
STEM
暂无分部数据
